Peripheral blood lymphocyte/monocyte ratio at the time of first relapse predicts outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma

Table 1 Baseline characteristics based on relapsed/primary refractory DLBCL patients with an ALC/AMC ratio ≥ 2.0 versus ALC/AMC ratio < 2.0

Characteristics	ALC/AMC ratio ≥ 2.0	ALC/AMC ratio < 2.0	P
Disease status
Primary reractory	37	57	<0.001
Relapse	53	16
Age (years)
<60	56	49	0.516
≥60	34	24
Gender
Male	46	27	0.096
Female	45	45
Karnofsky
Performance status
80% or more	79	52	0.008
Less than 80%	11	21
Number of extra nodal sites
≤1	74	58	0.654
>1	16	15
Ann Arbor Stage
I/II	44	18	0.002
III/IV	16	55
LDH
≤Normal	65	40	0.021
>Normal	25	33
SaaIPI
0	34	13	0.002
1	34	23
2	18	25
3	4	12
Initial chemotherapy
CHOP	52	31	0.052
R-CHOP	38	42
Rituximab-containing salvage therapy
No	61	59	0.060
Yes	29	14
ASCT
No	78	67	0.300
Yes	12	6
Salvage therapy
DHAP	6	2	0.304
DICE	14	13
ICE	23	25
GDP	16	19
R-DHAP	2	1
R-DICE	10	7
R-ICE	12	4
R-GDP	7	2

Abbreviations: ALC/AMC ratio absolute lymphocyte count/absolute monocyte count ratio, LDH lactate dehydrogenase, saaIPI second-line age-adjusted International Prognostic Index, CHOP cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone, R-CHOP rituximab- cyclophosphamIde, hydroxydaunorubicin, vincristine, prednisone, ASCT autologous stem cell transplantation, DHAP dexamethasone, cytarabine, and cisplatin, DICE dexamethasone, ifosfamide, cisplatin, and etoposide, ICE ifosfamide, carboplatin, and etoposide, GDP gemcitabine, cisplatin, and dexamethasone, R-DHAP rituximab, dexamethasone, cytarabine, and cisplatin, R-DICE rituximab, dexamethasone, ifosfamide, cisplatin, and etoposide, R-ICE rituximab, ifosfamide, carboplatin, and etoposide, R-GDP rituximab, gemcitabine, cisplatin, and dexamethasone.

ISSN: 1471-2407